Last reviewed · How we verify

platelet rich fibrin

Abeer hassan sharafuddin · FDA-approved active Biologic Quality 5/100

Platelet rich fibrin, marketed by Abeer Hassan Sharafuddin, is a therapeutic product currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameplatelet rich fibrin
Also known asplatelet concentrate, PRF, Natural growth factor
SponsorAbeer hassan sharafuddin
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: